A Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-Bendamustine for Relapsed/Refractory FL Patients Not Eligible for ASCT

Trial Profile

A Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-Bendamustine for Relapsed/Refractory FL Patients Not Eligible for ASCT

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms FIL_RENOIR12
  • Most Recent Events

    • 28 Dec 2017 Planned End Date changed from 1 Sep 2019 to 1 May 2021.
    • 28 Dec 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Nov 2018.
    • 28 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top